The OJC Episode 28: ASCO GU Roundtable

Pinterest LinkedIn Tumblr +

Eva Segelov and Craig Underhill are joined by Philip Parente and Carmel Pezaro for this ASCO GU Special, also featuring a Guest Interview with Michael Hofman.

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 28 in our series The Oncology Journal Club.

This week we are focused on the recent ASCO GU Symposium. We start with a roundtable discussion of the key papers with some very insightful guests – Eva Segelov and Craig Underhill are joined by Phillip Parenteee and Carmel Pezaro.

Eva also catches up with Michael Hofman to chat about his Lutetium PSMA trial.

We hope you enjoy today’s entertaining and informative episode.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


Previous Episodes of Interest:

  1. The Oncology Journal Club Episode 23: ASCO GI Special
  2. The OJC Episode 25: IASLC World Conference on Lung Cancer Part 1
  3. The OJC Episode 26: IASLC World Conference on Lung Cancer Part 2

This Week’s Papers:

  1. Bajorin, D.F., et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 39, 2021 (suppl 6; abstr 391). DOI: 10.1200/JCO.2021.39.6_suppl.391. Access online here.
  2. Powles, T., et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.  J Clin Oncol 39, 2021 (suppl 6; abstr 393). DOI: 10.1200/JCO.2021.39.6_suppl.393. Access online here.  (Simultaneous NEJM publication: Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med 2021; 384:1125-1135. DOI: 10.1056/NEJMoa2035807. Access online here.)
  3. Chi, K.N., et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). J Clin Oncol 39, 2021 (suppl 6; abstr 11). DOI: 10.1200/JCO.2021.39.6_suppl.11. Access online here.
  4. De Bono, J.S., et al. Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound. J Clin Oncol 39, 2021 (suppl 6; abstr 126). DOI: 10.1200/JCO.2021.39.6_suppl.126. Access online here.
  5. Chi, K.N., et al. Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study. J Clin Oncol 39, 2021 (suppl 6; abstr 26). DOI: 10.1200/JCO.2021.39.6_suppl.26. Access online here.
  6. De Bono, J.S., et al. PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer. J Clin Oncol 39, 2021 (suppl 6; abstr 13). DOI: 10.1200/JCO.2021.39.6_suppl.13. Access online here.
  7. Motzer, R.I., et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol 39, 2021 (suppl 6; abstr 269). DOI: 10.1200/JCO.2021.39.6_suppl.269. Access online here.
  8. Cella, D., et al. Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial. J Clin Oncol 39, 2021 (suppl 6; abstr 285). DOI: 10.1200/JCO.2021.39.6_suppl.285. Access online here.
  9. Pal, S.K., et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. J Clin Oncol 39, 2021 (suppl 6; abstr 270). DOI: 10.1200/JCO.2021.39.6_suppl.270. Access online here.

This Week’s Quick Bites:

  1. Chamie, Karim et al. Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients. J Clin Oncol 39, 2021 (suppl 6; abstr 510). DOI: 10.1200/JCO.2021.39.6_suppl.510. Access online here.
  2. Rini, B.I., et al. TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. J Clin Oncol 39, 2021 (suppl 6; abstr 278). DOI 10.1200/JCO.2021.39.6_suppl.278. Access online here.
  3. Ghadjar, P., et al. Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial. J Clin Oncol 39, 2021 (suppl 6; abstr 194). DOI: 10.1200/JCO.2021.39.6_suppl.194. Access online here.
  4. Choueiri, T.K., et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 39, 2021 (suppl 6; abstr 272). DOI: 10.1200/JCO.2021.39.6_suppl.272. Access online here.

This Week’s Interview:

  1. Hofman, M, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, Volume 397, Issue 10276, 797 – 804. Access online here.

Other Resources:

ANZUP Clinical Trials Group


This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Dr Carmel Pezaro

Carmel Pezaro

Dr Pezaro is a medical oncologist with particular interests in prostate cancer and clinical and translational research. She trained in New Zealand and Australia and commenced consultant practice in 2009. After completing a basic science doctorate through the University of Melbourne, she spent two years working as a clinical trials fellow at the Royal Marsden NHS Foundation Trust, under the mentorship of Professor Johann de Bono. From 2013-2018 Dr Pezaro worked as a medical oncologist in Melbourne Australia, where she was actively involved in cooperative group research, served on national research advisory committees and was elected to the Economic Sub-Committee of the Pharmaceutical Benefits Advisory Committee. In 2019, Dr Pezaro will begin a five-year Senior Clinical Research Fellowship with Yorkshire Cancer Research.

You can find Carmel on Twitter here: @pezaro_c

Associate Professor Phillip Parente

Phillip Parente

A/Prof Phillip Parente trained at Monash University graduating with First Class Honours in 1993. He completed training in Medical Oncology 2001 and completed a 2year Fellowship in Immunology and Melanoma at Ludwig Institute for Cancer Research at Austin Health. Initially he worked as a Medical Oncologist at both Eastern Health and Austin Health. His current role is the Director of Cancer Services Eastern Health

His main areas of interest are Genitourinary Cancers, Lung Cancers and Melanoma and he is considered a clinical lead in these areas of oncology. With respect to oncology research he is principal investigator of numerous trials in his areas of interest. This has translated to numerous publications and presentations at local and international oncological conferences.

A/Prof Parente has professional interest in teaching and training. He is a senior member of the National Examining Panel for the Royal Australasian College of Physicians and past chair Advanced Trainee Committee Medical Oncology for the Royal Australasian College of Physicians. He is also the current Treasurer and Executive Committee Member of the Medical Oncology Group of Australia, (MOGA).

A/Prof Phillip Parente has completed a Master of Health and Medical Law in 2020 and currently completing a Master of Human Rights Law at the Faculty of Law, Melbourne University.

You can find Phillip on Twitter here: @ParentePhillip

Professor Michael Hofman

Michael Hofman

Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy’s & St Thomas’ in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in conology. This includes neuroendocrine tumours and haematologic applications and more recently has focussed on improving outcomes for men with prostate cancer.

Dr Hofman has a strong track record leading Phase I, II and III clinical trials ranging from first-in-human evaluation of novel radiopharmaceuticals to conducting large mutli-centre randomised clinical trials. In the latter, through his involvement on the scientific committee of the The Australasian Radiopharmaceutical Trials Network (ArtNet), he has established a network of more than 10 centres around Australia with multi-disciplinary expertise culminated in research presented at leading conferences (ESMO, ASCO, EAU) and published in high impact journal such as The Lancet. He has active grants as chief investigator totalling more than $15 million dollars including the Prostate Cancer Foundation (PCF), Movember, Medical Research Future Fund (MRFF), Prostate Cancer Foundation of Australia (PCFA) and the U.S. Department of Defence.

Find Michael on Twitter here: @DrMHofman

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Phillip Parente, Carmel Pezaro, Michael Hofman and Graham Knowles.

 

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.